• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

    2/16/23 3:11:00 PM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email
    SC 13G/A 1 hbio13g.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Harvard Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 416906105 (CUSIP Number) December 31, 2022** (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. **This Schedule 13G/A amends and restates the Schedule 13G filed by the Reporting Persons on February 15, 2023 in its entirety. The information required in the remainder of this cover page shall not be deemed to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 NAME OF REPORTING PERSON B. Riley Asset Management LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 3,264,796 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 3,264,796 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,264,796 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% 12 TYPE OF REPORTING PERSON IA 1 NAME OF REPORTING PERSON Wes Cummins 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 3,264,796 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 3,264,796 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,264,796 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% 12 TYPE OF REPORTING PERSON IN Item 1(a). NAME OF ISSUER Harvard Bioscience, Inc. Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES 84 October Hill Road, Holliston, MA 01746 Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) B. Riley Asset Management LLC, a Delaware limited partnership ('BRAM'), with respect to the shares of Common Stock directly held by 272 Capital Master Fund Ltd. ('Fund') to which BRAM acts as investment manager, and other advisory accounts of BRAM and (ii) Wes Cummins ('Mr. Cummins', and together with BRAM, the 'Reporting Persons'), who is the President of BRAM. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 3811 Turtle Creek Blvd, Suite 2125, Dallas, TX 75219. Item 2(c). CITIZENSHIP B. Riley Asset Management LLC is a Delaware limited partnership. Mr. Cummins is a United States citizen. Item 2(d). TITLE OF CLASS OF SECURITIES Common Stock, par value $0.01 per share (the 'Common Stock') Item 2(e). CUSIP NUMBER 416906105 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a)[ ] Broker or dealer registered under Section 15 of the Act; (b)[ ] Bank as defined in Section 3(a)(6) of the Act; (c)[ ] Insurance company as defined in Section 3(a)(19) of the Act; (d)[ ] Investment company registered under Section 8 of the Investment Company Act of 1940; (e)[x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f)[ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii) (F); (g)[x] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h)[ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i)[ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j)[ ] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. OWNERSHIP The percentages set forth herein are calculated based upon 41,657,688 shares of Common Stock outstanding as of October 31, 2022 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed by the Issuer with the Securities and Exchange Commission on November 8, 2022. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference. Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not applicable. Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON See Item 2. 272 Capital Master Fund Ltd. has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock. Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON Not applicable. Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. Item 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. Item 10. CERTIFICATION Each Reporting Person hereby makes the following certification: By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 16, 2023 B. Riley Asset Management LLC By: /s/ Wes Cummins Name: Wes Cummins Title: President Wes Cummins By: /s/ Wes Cummins Name: Wes Cummins
    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings

    $HBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Cote Jennifer covered exercise/tax liability with 5,687 shares, decreasing direct ownership by 3% to 159,019 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      3/21/25 4:50:40 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Green James W covered exercise/tax liability with 38,413 shares, decreasing direct ownership by 1% to 2,845,088 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      3/21/25 4:49:38 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Green James W returned 145,365 shares to the company, decreasing direct ownership by 5% to 2,883,501 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      1/3/25 4:15:27 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces CFO Transition

      HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and Treasurer. Ms. Cote's resignation will be effective upon the filing of the Company's Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote's resignation. Mr. Frost brings over 30 years of financial and executive-level management experience from both private and public companies. He has served as a consultant to the Company since January 2025. Mr. 

      4/10/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

      HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO's website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on

      3/12/25 4:00:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.

      SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      5/8/25 12:45:14 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Harvard Bioscience Inc.

      DEFA14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      4/21/25 4:45:55 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Harvard Bioscience Inc.

      DEF 14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      4/21/25 4:45:39 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harvard Bioscience Inc.

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      11/14/24 12:31:23 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Harvard Bioscience Inc.

      SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      3/19/24 1:02:15 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Harvard Bioscience Inc. (Amendment)

      SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)

      2/14/24 4:05:25 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/14/24 4:02:29 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/7/24 4:02:24 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Harvard Biosci downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight

      4/9/25 8:35:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Biosci upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously

      3/10/23 8:11:48 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • KeyCorp reiterated coverage on Harvard Bioscience with a new price target

      KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously

      3/10/21 5:04:31 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Financials

    Live finance-specific insights

    See more
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

      HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, "Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, "We are encouraged by the strong mark

      3/12/25 7:21:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentati

      2/24/25 11:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

      HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Jim Green, Chairman and CEO said, "Originally joining us as our Vice President of Global Finance, Jennifer brought extensive experience in areas including global financial and operational leadership, corporate strategy, accounting and internal controls, and strong fiscal management. Since assuming the

      6/20/23 8:01:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials